Leucine/metformin

Drug Profile

Leucine/metformin

Alternative Names: L-leucine/metformin; Metformin/L-leucine; Metformin/leucine; NS-0100

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator NuSirt Biopharma
  • Class Antihyperglycaemics; Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sirtuin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 23 Mar 2017 Phase-II development for Type-2 diabetes mellitus is ongoing in USA (PO)
  • 26 Jan 2016 NuSirt Biopharma completes a phase IIa trial in Type-2 diabetes mellitus in USA , (NCT02151461)
  • 25 Jun 2015 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus released by NuSirt Biopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top